Save time and jump to the most important pieces.
SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (NASDAQ:VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development. VivoSim will offer liver and intestinal toxicology insights using its premier new approach methodologies (NAM) models, following the announcement of the FDA to phase out animal testing requirements in favor of these non-animal NAM methods. The FDA's push to phase out animal models, announced on April 10, is expected to provide a powerful accelerant to VivoSim's market adoption, disrupting a >$10B animal testing market with models that are more predictive and ethically sound. As FDA Commiss
SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) (the "Company") announced that it will carry forward its 3D bioprinting and legacy technology as VivoSim Labs, Inc. A name change of the Company to VivoSim Labs, Inc. will be effective on April 24, 2025, and the Company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "VIVS" at market open on April 24, 2025. No action is required by existing stockholders with respect to the name and ticker symbol change. The Company's common stock will continue to be listed on the Nasdaq Capital Market and the CUSIP number assigned to the Company's common stock (68620A302) wil
SAN DIEGO, April 02, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD), today reported preliminary unaudited cash for the fiscal year ending March 31, 2025, and net cash utilization results for the fiscal fourth quarter of 2025. The Company expects to release full fiscal second-quarter financial results the week of June 9-13, 2025. The Company also gave guidance that, as its common stock has been trading above the $1.00 minimum bid price required, it expects to meet the requirements for continued listing on the Nasdaq Capita
SC 13G - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)
SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)
SC 13G/A - ORGANOVO HOLDINGS, INC. (0001497253) (Subject)
8-K - VivoSim Labs, INC. (0001497253) (Filer)
8-K - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)
424B5 - ORGANOVO HOLDINGS, INC. (0001497253) (Filer)
3 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
4 - ORGANOVO HOLDINGS, INC. (0001497253) (Issuer)
BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE:MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the "Effective Date"). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. "We are thrilled to announce the addition of Keith and Edward to our Board," stated Jerome D. Jabbour, Chief Executive Officer of Matinas. "Their deep industry experience, leadership expertise, and capital markets acumen will be of great value as we move the company forward into a new era continu
SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announced that it had appointed Norman Staskey as Chief Financial Officer. Mr. Staskey has worked for Danforth Advisors since 2021, working as Chief Financial Officer for clients such as Azitra, Inc., a biotechnology company developing novel dermatology therapeutic technologies. Norm has over 25 years working in capital market and M&A transactions most recently as a Managing Director in EY's (formally Ernst & Young) national transactions practice wh